Research question and objectives Primary endpoint
• To evaluate the effectiveness of Rimegepant in the acute treatment of migraine as measured by most severe pain, onset of pain relief, satisfaction with pain relief, and satisfaction with return to normal function post-dose.
Secondary Objectives
To evaluate the effectiveness of Rimegepant in the acute treatment of migraine as measured by onset of associated symptoms relief.
To evaluate the long-term effect of Rimegepant treatment on the treatment satisfaction and global impression of change at months 3，6 and 12.
Exploratory Objective
To evaluate the long-term effectiveness of Rimegepant by evaluating the changes from baseline in any decrease in MMD with any intensity in those participants with baseline MMD ≥6 days.
To evaluate the long-term effectiveness of Rimegepant by evaluating the changes from baseline of any decrease of MHD.
To evaluate the long-term effectiveness of Rimegepant by evaluating any decrease of mean number of moderate to severe migraine days per month in those participants with baseline MMD ≥6 days
To evaluate the changes from baseline in the percentage of MOH and chronic migraine transformation to episodic migraine during Rimegepant long-term (PRN) use.
To evaluate the changes from baseline of Rimegepant usage, other migraine-related medication usage and MO during Rimegepant long-term (PRN) use.
To evaluate the changes from baseline on quality of life, function, depression and anxiety at months 3, 6 and 12.
To evaluate the association between the timing of Rimegepant dosing (dosing at pain free while with any prodrome symptoms/ dosing at pain free while with any aura symptoms / dosing at mild pain/ dosing at moderate pain/ dosing at severe pain) and the acute treatment effectiveness of Rimegepant.
To evaluate the acute treatment effectiveness of Rimegepant in migraine participants with a history of insufficient response or intolerable to NSAIDs /Triptans /Combination analgesic.
To evaluate the acute treatment effectiveness of combination use of Rimegepant plus NSAIDs/Triptans/Combination analgesic in participants with insufficient response to monotherapy.
To evaluate the acute treatment effectiveness of Rimegepant in migraine participants with prior treatment failure of more than two triptans.
Study design This is a single arm, prospective, multi-center, observational registry study with participants receiving Rimegepant for the acute treatment of migraine in a real-world setting. Each participant will receive treatment and care according to standard clinical practice.
About 3,000 adult migraine participants will be enrolled continuously at 70 to 73 sites with a headache clinic or headache center in China in approximately 16 consecutive months or until reaching the target sample size.. The index date for a participant will be the date of enrollment. The maximum follow-up period per participant after enrollment is 12 months.
At the Baseline Visit, the demographics information, socioeconomic characteristics, and medical and migraine history will be collected from the enrolled participants. For the acute treatment effectiveness evaluation, data on Rimegepant treating single migraine attack including the timing of dosing, most severe pain, onset time of pain relief, onset time of associated symptoms relief, satisfaction with pain relief and satisfaction with function improvement are expected to be captured within 3 months after enrollment through a digital platform. If none of these data are captured within 3 months, the participant will be marked as failed in the study and will not be followed up further. For the long-term effectiveness evaluation, participants will use an eDiary to record headache and migraine occurrence, and use a digital platform to collect Rimegepant and other migraine-related medication usage days every month. At study visits, participants will complete the Migraine-Specific Quality-of-Life Questionnaire (MSQ) v2.1, Migraine Disability Assessment (MIDAS), Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder -7 (GAD-7), Patient Global Impression of Change (PGI-C) and the Satisfaction with Medication (SM) scale at months 3, 6 and 12 via electronic patient reported outcomes (ePROs). The previous four scales will be completed by participants at baseline visit.

开始日期2024-08-01

申办/合作机构

中国人民解放军总医院

NCT06473597 / Not yet recruiting临床4期IIT

A Comparison of Rimegepant Orally Disintegrating Tablet (Nurtec ODT) to Rizatriptan Benzoate Orally Disintegrating Tablet (Maxalt MLT-ODT) in Adult Patients Presenting to the ED With Migraine Headache: Randomized, Double-Blind, Clinical Trial

Rimegepant (Nurtec) is an orally administered small molecule CGRP receptor antagonist with efficacy in the acute treatment of migraine. Rizatriptan benzoate (MAXALT), is a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist. Rizatriptan binds with high affinity to human cloned 5-HT1B and 5-HT1D receptors which leads to activation of these receptors results in cranial vessel constriction, inhibition of neuropeptide release and reduced transmission in trigeminal pain pathways with resultant relieve of the headache.
Teh investigators hypothesize that the administration of Rimegepant ODT would provide better analgesic efficacy than Rizatriptan ODT with respect to analgesic efficacy at 60 min and 120 minutes in ED patients with acute headache.
This is a prospective, randomized, double-blind superiority trial evaluating and comparing analgesic efficacy and safety of Rimegepant ODT 75 mg to Rizatriptan ODT 10 mg in adult patients presenting to the Emergency Department of Maimonides Medical Center with acute migraine headache.

开始日期2024-07-01

申办/合作机构

Maimonides Medical Center

NCT06221111 / Recruiting临床2期

Rimegepant, a CGRP Antagonist, in the Treatment of Visceral Sensation and Chronic Abdominal Pain: A Pilot Study

The primary aim of this study is to evaluate the efficacy of rimegepant on abdominal pain scores in participants with non-constipation IBS.

开始日期2024-06-06

申办/合作机构

Mayo Clinic

[+1]

100 项与硫酸瑞美吉泮相关的临床结果

登录后查看更多信息

100 项与硫酸瑞美吉泮相关的转化医学

登录后查看更多信息

100 项与硫酸瑞美吉泮相关的专利（医药）

登录后查看更多信息

167

项与硫酸瑞美吉泮相关的文献（医药）

2024-12-31·Journal of medical economics

Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK

Article

作者: Ahern, Aideen ; Jenkins, Aaron ; Tran, Thang ; Large, Sam ; Popoff, Evan ; L'Italien, Gil J ; Powell, Lauren C ; Johnston, Karissa ; Pawinski, Robert

AIMS:

Migraine is the most common disabling headache disorder and is characterized by recurrent throbbing head pain and symptoms of photophobia, phonophobia, nausea, and vomiting. Rimegepant 75 mg, an oral lyophilisate calcitonin gene-related peptide antagonist, is the first treatment approved for both the acute and preventative treatment of migraine, and the first acute therapy approved in over 20-years. The objective was to assess the cost-utility of rimegepant compared with best supportive care (BSC) in the UK, for the acute treatment of migraine in the adults with inadequate symptom relief after taking at least 2 triptans, or for whom triptans are contraindicated or not tolerated.

MATERIALS AND METHODS:

A de novo model was developed to estimate incremental costs and quality-adjusted life years (QALYs), structured as a decision tree followed by Markov model. Patients received rimegepant or BSC for a migraine attack and were assessed for response (pain relief at 2-h). Responders and non-responders followed different pain trajectories over 48-h cycles. Non-responders discontinued treatment while responders continued treatment for subsequent attacks, with a proportion discontinuing over time. Data sources included a post-hoc pooled analysis of the phase 3 acute rimegepant trials (NCT03235479, NCT03237845, NCT03461757), and a long-term safety study (NCT03266588). The analysis was conducted from the perspective of the UK National Health Service and Personal Social Services over a 20-year time horizon.

RESULTS:

Rimegepant resulted in an incremental cost-utility ratio (ICUR) of £10,309 per QALY gained vs BSC, which is cost-effectiveness at a willingness to pay threshold of £30,000/QALY. Rimegepant generated +0.44 incremental QALYs and higher incremental lifetime costs (£4,492). Improved QALYs for rimegepant were a result of less time spent with severe and moderate headache pain.

CONCLUSION:

This study highlights the economic value of rimegepant which was found to be cost-effective for the acute treatment of migraine in adults unsuitable for triptans.

2024-12-01·CNS & Neurological Disorders-Drug Targets

Safety and Efficacy of Calcitonin Gene-related Peptide Receptor Antagonists and Selective Serotonin Receptor Agonist in the Management of Migraine: A Systematic Review and Meta-analysis

Article

作者: Datusalia, Ashok Kumar ; Singh, Pooja ; Kumar, Anoop ; Ponnada, Rakesh Kumar ; Sharma, Ruchika ; Sumadhura, Bommaraju

Background:::

Recently, US Food and Drug Administration (FDA) has approved calcitonin gene-related peptide receptor antagonists (rimegepant, and ubrogepant), and selective serotonin receptor agonists (lasmiditan) in the management of migraine. However, the exact safety and efficacy profile of these drugs is unclear so far.

Methods:::

The study’s primary objective was to determine the exact safety and efficacy profile. The overall estimate was calculated in terms of risk ratios using a suitable model. The subgroup analysis was also performed to check the effect of individual drugs on the outcome, whereas sensitivity analysis was performed to check the effects of outliers on the outcome. All the analyses were performed using Rev Man 5. The drugs have shown significant improvement in efficacy parameters (pain freedom, most bothersome symptoms, phonophobia, nausea, and photophobia).

Results:::

The subgroup analysis results have shown significant improvement in all efficacy parameters in the rimegepant and ubrogepant groups. The effect of ubrogepant on safety parameters was found to be non-significant, indicating a better safety profile of ubrogepant than lasmiditan.

Conclusion:::

The sensitivity analysis results have shown no effect of outliers on the efficacy parameters. Based on the available evidence, recently approved drugs are effective in the treatment of migraine, however, associated with few adverse drug reactions.

2024-10-01·Pain and Therapy

Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study

Article

作者: Croop, Robert ; True, David ; Mullin, Kathleen

INTRODUCTION:

Cardiovascular (CV) risk factors can limit treatment options for migraine. Rimegepant is an orally administered small-molecule calcitonin gene-related peptide receptor antagonist that does not induce vasoconstriction. The aim of these post hoc subgroup analyses was to assess the safety of rimegepant according to CV risk.

METHODS:

In a multicenter, long-term, open-label, phase II/III safety study, participants with a history of 2-14 migraine attacks per month of moderate or severe pain intensity self-administered rimegepant 75 mg, orally, to treat migraine up to once daily for up to 52 weeks. Uncontrolled, unstable, or recently diagnosed CV disease was part of the exclusion criteria. Safety was assessed across subgroups according to number of CV risk factors (0, 1, or ≥ 2) and Framingham Risk Score (< 10% or ≥ 10%).

RESULTS:

Of 1800 treated participants, 28.8% had one CV risk factor and 12.1% had ≥ 2 CV risk factors; 7.0% had Framingham Risk Score ≥ 10%. Across the subgroups with 0, 1, and ≥ 2 CV risk factors and Framingham Risk Score < 10% and ≥ 10%, respectively, proportions of participants reporting adverse events (AEs; 59.6%, 61.4%, 62.2%, 59.9%, 67.5%) and serious AEs (2.7%, 2.5%, 2.3%, 2.6%, 2.4%) were consistent, and AEs leading to study drug discontinuation were low (1.9%, 3.1%, 5.5%, 2.5%, 4.8%).

CONCLUSIONS:

Rimegepant showed favorable safety and tolerability in adults with migraine and CV risk factors, including those with moderate to high CV risk.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT03266588.

226

项与硫酸瑞美吉泮相关的新闻（医药）

2024-09-19

·FiercePharma

New migraine drugs less effective than previous generation of triptan meds: BMJ study

A meta-analysis of 137 trials of migraine drugs indicates that the newest class of treatments are less effective than the previous generation of triptan drugs in relieving acute headaches. A study from The BMJ indicates that the newest class of migraine drugs—which includes Pfizer’s Nurtec, AbbVie’s Ubrelvy and Eli Lilly’s Reyvow—is less effective in the acute treatment of migraines than a previous class of medicines.What's more, the newer drugs are no more effective in treating migraines than traditional headache remedies such as Tylenol, ibubrofen and aspirin, according to The BMJ's analysis.The study, a meta-analysis of 137 trials that together enrolled nearly 90,000 patients, indicates that the most effective treatments for migraine come from the triptan class. In head-to-head comparisons of the 17 drugs covered in the study, triptans demonstrated the best efficacy within 2 hours of use, led by eletriptan, which also delivered the best-sustained relief over 24 and 48 hours, according to the analysis.Eletriptan was brought to the market by Pfizer in 2002 and sold under the brand name Relpax. The next most effective medicines in providing relief at 2 hours were the following triptans (in order of performance): rizatriptan, sumatriptan and zolmitriptan. Rizatriptan is sold by Organon as Maxalt. GSK sells sumatriptan as Imitrex and AstraZeneca markets zolmitriptan as Zomig.“Triptans are currently widely underused, and access to the most effective triptans should be promoted globally and international guidelines updated accordingly,” the authors wrote. The BMJ analysis also concluded that the newest class of migraine treatments—which are called calcitonin gene-related peptide receptor (CGRP) antagonists—should only be used after traditional headache meds.“While the recent introduction of lasmiditan (Reyvow), rimegepant (Nurtec), and ubrogepant (Ubrelvy) has expanded options for the acute treatment of migraine, the high cost of these newer drugs, along with the substantial adverse effects of lasmiditan, suggest their use as third-line options, after the less expensive, similarly efficacious, second-line options," the authors wrote.While the BMJ study focused on acute treatment of migraines, new CGRP treatments have also been approved as preventatives. Nurtec pills, for example, were approved in 2021 for use every other day to ward off potential migraines. Much hope has been pinned on the effectiveness of CGRP drugs. In 2022, Pfizer spent $11.6 billion in a buyout of Biohaven to gain Nurtec, which rolled up sales of $928 million last year. Meanwhile, Ubrelvy, which was approved in 2019, generated $815 million in sales.Several other CGRPs—all approved in 2018 for the prevention of migraines—also remain formidable. Eli Lilly’s Emgality generated $678 million in sales last year, while Teva’s Ajovy pulled in $435 million and Amgen’s Aimovig collected $303 million. Besides those drugs, Lundbeck's Vyepti won approval in 2020 and generated about $250 million last year.

上市批准并购临床结果

2024-09-13

·FiercePharma

Tonix questions efficacy of oral migraine drugs in awareness campaign

Tonix is set to launch a disease education website to explain the link between gastroparesis and migraine. Tonix Pharmaceuticals is trying to start a conversation about a potential shortcoming of oral migraine drugs, kicking off a national campaign to raise awareness of a condition that can affect absorption.The company’s commercial subsidiary, Tonix Medicines, markets two formulations of sumatriptan for use in migraine. Sumatriptan was approved more than 30 years ago. Dr. Reddy’s Laboratories received FDA approval for an injectable formulation, Zembrace SymTouch, in 2016 and a nasal spray version in 2019. Tonix acquired the products in 2023.Facing off against oral drugs such as AbbVie’s Ubrelvy, Tonix is seeking to raise awareness of potential benefits of nasal and injectable formulations with the “Does Your Migraine Pill Work Every Time?” Tonix launched the campaign at the PAINWeek 2024 National Conference in Las Vegas.The question posed in the educational campaign reflects studies showing a link between gastroparesis and migraine. Gastroparesis is defined by the delayed emptying of the contents of the stomach into the intestine, potentially causing symptoms such as vomiting. Studies show some patients have migraine and gastroparesis at the same time. If that happens, gastroparesis could limit the absorption of oral drugs. “Non-oral migraine medications, such as injectables and nasal sprays, do not rely on the digestive system to be absorbed and can offer the potential for faster relief from migraine symptoms in as little as 10 minutes,” the University of Texas Southwestern Medical Center’s Deborah Friedman, M.D., said in a statement. Friedman encourages patients and doctors to discuss adding non-oral options to their treatment plans.Tonix is set to launch a disease education website to explain the link between gastroparesis and migraine and why oral medicines may not work. The company has also scheduled a webinar on the topic for next week.Spreading the word about situations in which oral drugs may be ineffective could benefit Tonix’s drugs, sales of which totaled $2.2 million in the second quarter. The figure makes Tonix a small player in the migraine market. Pfizer reported $356 million in sales of Nurtec ODT, which dissolves in the mouth, over the same period. AbbVie’s Ubrelvy and Qulipta generated a combined $381 million.

上市批准

2024-09-04

·BioSpace

Lilly, Pfizer Take Meds Straight To Consumers in Renewed DTC Push

Various kinds of medical pills with Rx sign on smartphone screen , online pharmacy concept Atstock Productions/iStock Big Pharma has finally gotten its arms around something advocates have wanted for a long time: direct-to-consumer sales. Eli Lilly and Pfizer are leading the way. Big Pharma is finally beginning to offer what patient advocates have been asking for: a direct-to-consumer option to buy medicines straight from the manufacturer. This past week, Eli Lilly announced the addition of starter Zepbound vials to its DTC platform, called LillyDirect, expanding options for patients to self-pay for the popular weight loss drug. A day later, Pfizer announced the digital portal PfizerForAll , which provides access to the New York pharma giant’s vaccines, plus migraine and respiratory drugs. The two programs connect patients to telehealth care and a third-party service for the delivery of medicine. “It does just make the full digital telehealth pharmacy experience online really seamless,” Dedham Group Principal Manny Jurado told BioSpace . “It’s like you’re able to integrate everything into almost more or less a one-stop shop.” Jurado says these DTC approaches are a long time coming. Advocates have been calling for a new way for patients to access medicines that could help bring down costs by cutting out the so-called middle-men that pharma industry groups say push up prices. But DTC adoption has been slow. These latest announcements are a welcome advancement, Jurado said. “I’m sure pharma already had a lot of plans about this multiple years ago, but it’s now finally that we’re able to see it come to fruition,” he said, acknowledging the complexity of developing these programs in terms of compliance and regulatory hurdles. While the process cuts out the trip to the pharmacy, patients are not exactly receiving the medicine from Lilly or Pfizer’s personal storage rooms. Jurado said the pharmas have contracted third-party providers for the actual distribution. He noted that the DTC idea is not new. Amgen and AbbVie have existing platforms and the pharma industry has played around with the idea previously with minimal success. Now that Lilly and Pfizer are diving in, he suspects more—including Lilly’s chief rival Novo Nordisk —will follow suit. Zepbound Pushes Lilly Toward DTC Option Lilly was a natural entrant given the craze around Zepbound and the supply hurdles the company has faced. LillyDirect launched in January , just two months after Zepbound’s approval. Then last week, Lilly announced the availability of single-dose vials of Zepbound at a 50% discount compared to the list price of other treatments in the incretin class. CEO David Ricks said during a fourth quarter earnings call in February that the idea came from the challenges patients have experienced accessing obesity treatment. “Finding medicines in their pharmacies, that’s a been a challenge,” Ricks said on the call. “And I think particularly as supplies are tight, many patients report driving to five, six, seven pharmacies to find the medicine they need. This simplifies that process.” The direct pharmacy also gives patients confidence that they are getting a genuine Lilly-manufactured drug, as compounded or illicit versions of Zepbound have trickled into the market, the CEO added. “We haven’t thought about it as a way to create some new retail distribution business. It’s a way to serve the patients that want our medicines better,” Ricks said. But Lilly will benefit from getting new patients started on treatment, Jurado said. While the online pharmacy serves as an option for patients whose insurance has denied coverage of the weight loss drug, the single-dose vial offered through LillyDirect is just a starter dose—patients will eventually have to step up to a higher dose which will need to be accessed another way, according to Jurado. In addition, as the coverage landscape for weight loss medication evolves, cash-pay patients will likely switch over to insurance and long-term care. Lilly did not frame the new vial offering as a way to cut costs for patients. The drug launched last year in its injectable form with a list price of $1,059.87 a month for the various doses. But removing the injectable from the equation does lead to a savings in terms of the overall price and some of the manufacturing complexity. A number of third-party providers have been pulled together to deliver LillyDirect. EVERSANA and others are conducting pre-authorizations; Form Health and 9amHealth are doing the telehealth services; and TruePill and Amazon Pharmacy are offering the pharmacy services, among other providers. Pfizer tackles an ‘overwhelming’ system While Lilly is doubling down in DTC, Pfizer is just getting started. With PfizerForAll, patients can purchase prescription drugs, over-the-counter medications and diagnostic tests, available for pick-up at a local pharmacy or through home delivery. The service will also connect patients with in-person or online appointments with healthcare professionals and offer a scheduling tool for adult COVID-19, flu, pneumococcal pneumonia and respiratory syncytial virus (RSV) vaccinations. In addition, PfizerForAll provides access to the company’s savings programs, which include solutions for co-pay and insurance. “People often experience information overload and encounter roadblocks when making decisions for themselves or their family in our complex and often overwhelming U.S. healthcare system. This can be extremely time-consuming and lead to indecision or inaction – and as a result, poor health outcomes,” Aamir Malik, Pfizer’s executive vice president and chief U.S. commercial officer, said in an August 27 statement. “We are pleased to offer PfizerForAll to help relieve this burden on people, especially as we enter the fall season in the U.S., and streamline the path for those seeking better health.” While Lilly is trying to address a nearly insatiable demand for its weight loss drug, Jurado said that migraine medicines have also been in demand. Pfizer markets Nurtec and Zavzpret. “We’re seeing more and more of these pseudo-retail type products and retail therapies starting to make more sense from a direct-to-consumer standpoint and ease of online access,” Jurado said, adding that migraine treatment requires a neurologist, which can be hard to access. Pfizer has stated plans to expand the program, potentially to a broader range of conditions. In announcing PfizerForAll, Pfizer also did not mention slashing prices as a reason behind the move. While the program connects patients to existing affordability programs, no new options were released to coincide with the DTC launch. Ready, Set, Launch When contacted by BioSpace , AbbVie pointed to the Synthroid Delivers program, which offers the brand name thyroid hormone medicine directly to patients for $25 per month for a 90-day prescription. AbbVie uses Eagle Pharmacy to fulfill the orders. Amgen did not return multiple requests for comment, but STAT identified the company as one that has used virtual care in the past for its migraine drugs. Jurado suspects there may soon be more companies joining the DTC marketplace. “I would assume that there’s going to be a lot of other players who are either potentially launching, or are even thinking about launching,” Jurado said.

100 项与硫酸瑞美吉泮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	硫酸瑞美吉泮	N02C	DB12457

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Pfizer Inc.	2020-02-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
颞下颌关节障碍	临床3期	美国	Pfizer Inc.	2022-05-05
慢性鼻窦炎伴鼻息肉	临床3期	美国	Pfizer Inc.	2022-02-17
鼻息肉	临床3期	美国	Pfizer Inc.	2022-02-17
先兆偏头痛	临床3期	美国	Pfizer Inc.	2021-04-28
先兆偏头痛	临床3期	波兰	Pfizer Inc.	2021-04-28
先兆偏头痛	临床3期	西班牙	Pfizer Inc.	2021-04-28
急性偏头痛	临床3期	中国	Pfizer Inc.	2020-10-22
急性偏头痛	临床3期	中国	标新有限公司	2020-10-22
急性偏头痛	临床3期	韩国	标新有限公司	2020-10-22
急性偏头痛	临床3期	韩国	Pfizer Inc.	2020-10-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03266588 (Pubmed) 人工标引	临床2/3期	偏头痛	1,800	Rimegepant (CV risk 0)	網廠醖襯繭衊夢選壓糧(糧衊齋夢繭壓淵蓋觸淵) = 願鏇築簾鑰憲構鬱積獵願憲製淵廠顧糧壓壓齋 (觸衊餘醖觸築鏇壓積遞 ) 更多	积极	2024-07-10
				Rimegepant (CV risk 1)	網廠醖襯繭衊夢選壓糧(糧衊齋夢繭壓淵蓋觸淵) = 艱願顧醖鹽膚壓遞簾廠願憲製淵廠顧糧壓壓齋 (觸衊餘醖觸築鏇壓積遞 ) 更多
NCT03235479 (Pubmed)	临床3期	偏头痛 calcitonin-gene receptor peptide (CGRP)	1,485	Rimegepant 75 mg oral tablet	糧積鑰餘顧壓憲窪獵衊(選遞衊襯窪觸襯壓簾齋) = 膚繭鏇遞範鑰網觸壓艱繭襯餘觸鹽築顧壓網淵 (淵製鏇艱艱顧積觸鏇顧 ) 更多	积极	2024-07-01
				Placebo	糧積鑰餘顧壓憲窪獵衊(選遞衊襯窪觸襯壓簾齋) = 艱製選顧糧顧觸範構獵繭襯餘觸鹽築顧壓網淵 (淵製鏇艱艱顧積觸鏇顧 ) 更多
NCT03941834 (BHV3000-202, CTgov)	临床2期	三叉神经痛	65	Rimegepant (DBT Phase: Pooled Rimegepant)	膚鏇選願醖憲夢衊範膚(醖願鑰餘構壓鬱艱範繭) = 夢鏇衊遞繭齋艱蓋鏇醖範憲網糧艱範選憲網願 (鬱鹽鏇蓋壓憲壓鏇繭鹽, 遞積製蓋鏇獵淵觸鏇壓 ~ 築廠夢構鹹衊餘遞顧蓋) 更多	-	2024-06-10
				placebo+rimegepant (DBT Phase: Pooled Placebo)	膚鏇選願醖憲夢衊範膚(醖願鑰餘構壓鬱艱範繭) = 膚艱構鹹齋衊獵顧簾夢範憲網糧艱範選憲網願 (鬱鹽鏇蓋壓憲壓鏇繭鹽, 獵顧齋範鑰糧網艱製願 ~ 製製觸淵廠構齋齋獵襯) 更多
NCT05262517 (CTgov)	临床3期	颞下颌关节障碍	126	Rimegepant (BHV3000 (Rimegepant (BHV3000))	範鬱蓋夢鹽窪鏇壓夢選(夢鬱簾餘顧鹽築範鏇製) = 獵壓蓋網艱積鑰夢繭夢廠鏇構製膚艱積繭願選 (繭壓願鹹鹽獵選積鏇鏇, 衊衊壓齋顧範網鏇鬱鬱 ~ 壓憲衊鹽衊觸築夢憲窪) 更多	-	2024-05-16
				placebo+rimegepant (Placebo)	範鬱蓋夢鹽窪鏇壓夢選(夢鬱簾餘顧鹽築範鏇製) = 選糧顧鹹觸製餘築鏇夢廠鏇構製膚艱積繭願選 (繭壓願鹹鹽獵選積鏇鏇, 壓鬱壓淵願鏇憲醖糧糧 ~ 選衊積醖遞蓋鏇獵廠廠) 更多
NCT04574362 (Pubmed) 人工标引	临床3期	急性偏头痛	1,075	Rimegepant 75 mg	蓋選製網積築築築壓糧(膚鏇選窪鹹積觸糧襯憲) = 艱築淵願廠齋夢壓製膚憲遞膚壓壓憲願願遞蓋 (襯衊壓遞構鏇獵鑰壓顧 ) 更多	积极	2024-04-16
				Placebo	蓋選製網積築築築壓糧(膚鏇選窪鹹積觸糧襯憲) = 顧鏇夢製願積構衊壓膚憲遞膚壓壓憲願願遞蓋 (襯衊壓遞構鏇獵鑰壓顧 ) 更多
NCT03266588 (Pubmed) 人工标引	临床2/3期	偏头痛 calcitonin gene-related peptide receptor	1,800	Rimegepant 75 mg PRN 2-8	繭鏇醖鹹衊壓遞夢膚襯(鏇構窪醖繭鏇顧範繭廠) = upper respiratory tract infection (8.8%), nasopharyngitis (6.8%) and sinusitis (5.1%). Most AEs were mild or moderate and considered unrelated to rimegepant. 範製襯範淵網膚積鏇膚 (衊簾網窪鏇構窪鑰積範 ) 更多	积极	2024-04-01
				Rimegepant 75 mg PRN 9-14
NCT04574362 (BHV3000-310, CTgov)	临床3期	急性偏头痛	1,648	Placebo	繭觸鏇選艱遞繭鏇獵鹹(鑰築蓋範淵鹽糧齋衊窪) = 鬱鑰淵醖製膚淵衊餘鏇積積鹹夢糧獵積範鏇顧 (觸憲襯鹹製繭鏇衊憲顧, 淵簾膚築蓋夢鹹蓋顧襯 ~ 蓋簾遞鑰鬱鑰繭築願築) 更多	-	2023-12-14
NCT04574362 (BHV3000-310, Pubmed)	临床3期	偏头痛	1,431	Rimegepant 75 mg	憲繭鬱鏇範構鬱糧憲糧(齋獵遞獵積選鏇廠選獵) = 7 [1%] of 668 vs 18 [3%] of 674 繭顧鹽積鹽夢鹽齋繭願 (範築鏇鏇艱選膚製築築 ) 更多	-	2023-06-01
				Placebo
P10-12.010 (AAN2023)	临床2/3期	偏头痛	-	Rimegepant 75 mg	艱製醖顧糧網醖鬱願夢(簾鹽夢餘窪顧積襯壓選) = 醖鏇範齋遞鹽鑰壓艱夢範築壓艱鏇廠網窪襯艱 (齋糧範鏇積淵鑰壓鏇鏇 ) 更多	-	2023-04-25
NCT03732638 (AAN2023)	临床2/3期	偏头痛	-	Rimegepant 75 mg	醖顧繭顧膚餘簾窪襯構(鹽簾築鬱觸齋鬱簾鏇網) = 廠範觸獵餘積窪壓憲選獵鏇構繭鹽積鏇艱網觸 (獵簾選鏇鹽襯獵繭糧觸, 92.9 ~ 96.7) 更多	-	2023-04-25